ClinicalTrialsFinder
RecruitingNot ApplicableNCT05657743

A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Advanced Pancreatic Cancer

Sponsor

Alpha Tau Medical LTD.

Enrollment

15 participants

Start Date

Aug 16, 2023

Study Type

INTERVENTIONAL

Conditions

Pancreatic CancerMetastatic Pancreatic CancerPancreatic AdenocarcinomaUnresectable Pancreatic Cancer

Summary

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer

Eligibility

Min Age: 18 Years

Inclusion Criteria17

  • Histologically and/or cytologically proven locally advanced or metastatic pancreatic adenocarcinoma
  • Patients must have i) received at least one line of chemotherapy OR ii) are medically unfit for further chemotherapy, AND iii) the tumor is still not deemed as resectable with radical surgery or the patient does not wish to go through surgery
  • Target lesion is technically amenable for at least 50% coverage by the Alpha DaRT seeds as determined by the treating physician
  • Interstitial radiation indication validated by a multidisciplinary team
  • Measurable lesion per RECIST (version 1.1) criteria
  • Lesion size ≤ 5 cm in the longest diameter
  • Age ≥18 years old
  • ECOG Performance Status Scale ≤ 2
  • Life expectancy is more than 6 months
  • WBC ≥ 3500/µl, granulocyte ≥ 1500/µl
  • Platelet count ≥60,000/µl
  • Calculated or measured creatinine clearance ≥ 60cc/min. Calculated or measured creatinine clearance can be≥ 40cc/min given stability of creatinine levels over the past three weeks (at least 1 test per week).
  • AST and ALT ≤ 2.5 X upper limit of normal (ULN)
  • INR \< 1.4 for patients not on Warfarin
  • Subjects are willing and able to sign an informed consent form
  • Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test before the Ra-224 implantation and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after brachytherapy.
  • Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy.

Exclusion Criteria13

  • Concomitant chemotherapy or immunotherapy within the past 4 weeks
  • Brain metastases
  • Borderline unresectable pancreatic cancer, and/or cases fit for surgical exploration unless patient refuses surgery
  • Known hypersensitivity to any of the components of the treatment.
  • Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids.
  • Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months.
  • Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial or interfere with the study endpoints.
  • Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
  • Patient requires treatment not specified in this protocol which may conflict with the endpoints of this study including evaluation of response or toxicity of DaRT.
  • Patients do not agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy.
  • Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.
  • High probability of protocol non-compliance (in opinion of investigator).
  • Breastfeeding women or women of childbearing potential unwilling or unable to use an acceptable contraceptive method to prevent pregnancy for 3 months after RT.

Interventions

DEVICERadiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)

An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms

Locations(2)

Wolfson Medical Center

Holon, Israel

Hadassah Ein Kerem

Jerusalem, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05657743

Related Trials

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

NCT056635158 locations

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

NCT046786483 locations

Resilience and Equity in Aging, Cancer, and Health (REACH)

NCT046742671 location

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

NCT0624477126 locations

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

NCT0697316127 locations